Clinical Trial Goal
To find out if the combination of belantamab mafodotin, dexamethasone and pomalidomide is safe and works well to treat high-risk multiple myeloma
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that doctors consider high risk
- Had an autologous (your own cells) blood or marrow transplant (BMT) within 1 year of diagnosis
- Do not have smoldering multiple myeloma, MGUS, amyloidosis or POEMS syndrome
- Do not have cancer cells in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Belantamab mafodotin is an antibody-drug conjugate, or combination, that combines belantamab with a chemotherapy (chemo) drug called mafodotin and targets BCMA on certain cells.
Dexamethasone is a drug that reduces inflammation.
Pomalidomide is a drug that blocks the growth of cancer cells.
You’ll get treatment in cycles that last 4 weeks. In each cycle, you'll get:
Dexamethasone is a drug that reduces inflammation.
Pomalidomide is a drug that blocks the growth of cancer cells.
You’ll get treatment in cycles that last 4 weeks. In each cycle, you'll get:
- Belantamab mafodotin – Given as intravenous (IV) infusions 1 time every other cycle
- Dexamethasone – A pill that you take by mouth 1 time each week
- Pomalidomide – A pill that you take by mouth 1 time each day for 3 weeks
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them to treat high-risk multiple myeloma is new and unproven.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them to treat high-risk multiple myeloma is new and unproven.
Locations
Emory University/Winship Cancer InstituteRECRUITING
Atlanta, Georgia
Bryan Burton, 404-778-1780, bryan.james.burton@emory.edu
Sponsors
collaborator: GlaxoSmithKline, collaborator: National Cancer Institute (NCI), lead: Emory University
